English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary  Haemophilia and its treatment interfere with patients' life, so health‐related quality of life ( HRQ oL) should be assessed when evaluating treatments. This study investigated the  HRQ oL of patients with haemophilia A treated prophylactically with a new recombinant factor  VIII . Two phase 3 trials investigated turoctocog alfa in patients with severe haemophilia A: one in children, one in adults and adolescents.  HRQ oL was a secondary endpoint assessed by the  HAEMO ‐ QOL  age‐specific, self‐administered questionnaires. Parent‐completed versions were also included for parents of children and adolescents. All  HAEMO ‐ QOL  questionnaires allow the calculation of domain‐specific and total scores ranging from 0 to 100, lower scores indicating better  HRQ oL. Mean change in all scores was described for 25 children aged 4–7 years, 21 children aged 8–12 years, 18 adolescents aged 13–18 years and 129 adults, overall, and according to the treatment regimen received prior to the study (on‐demand; prophylaxis; mixed). Mean changes in  HAEMO ‐ QOL  total score were 1.4 for children aged 4–7 years, −2.6 for children aged 8–12 years, −5.8 for adolescents and −1.6 for adults. In parent‐completed versions, mean changes in total score were −6.0 for children aged 4–7 years, −4.7 for children aged 8–12 years, and −10.0 for adolescents. Patients receiving on‐demand treatment before the trial showed greater improvement in  HRQ oL scores than patients already on prophylaxis.  HRQ oL of patients remained fairly stable over the course of the trials. However, improvements were observed for adolescents. Switching to prophylaxis was identified as a potential driver of improvement of  HRQ oL in patients with haemophilia A.

haemophilia

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa